Drug firm Lupin has launched its antidepressant Bupropion Hydrochloride extended release tablets used for treatment of major depressive disorder in the US market.
The company has launched its generic tablets in the strengths of 150 mg and 300 mg after having received approval from the United States Food and Drug Administration (USFDA), Lupin said in a BSE filing today.
The company’s tablets are generic versions of Valeant Pharmaceuticals North America LLC’s Wellbutrin XL Tablets in the same strengths, it added.
The product is indicated for treatment of major depressive disorder (MDD) and prevention of seasonal affective disorder in adults.
“Wellbutrin XL tablets had sales of USD 758 million as per IMS MAT May 2017”, Lupin said.
The Lupin stock gained 0.36 per cent to end at Rs 1,185 on the BSE.